US · Healthcare · Biotechnology
EPS came in at -1.02 against a street estimate of -0.83 — a miss of 22.9%.
Analysts rate Arcus Biosciences Inc a buy (11 buy, 2 hold, 0 sell out of 13) with an average price target of $36.83.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.11% |
| Wellington Management Company LLP | 4.84% |
| State Street Corp | 4.30% |
| Suvretta Capital Management, LLC | 4.00% |
| Vanguard Portfolio Management, LLC | 3.40% |
| Vanguard Capital Management, LLC | 3.07% |
| Woodline Partners LP | 3.00% |
| Marshall Wace Asset Management Ltd | 2.99% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-12 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-21 |
| Company announcement · Q2 2026 | 2026-04-20 |
| Board / officer change · Q1 2026 | 2026-03-23 |
| Annual report FY2025 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-10-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Arcus Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.